Longeveron (LGVN) announced that the Canadian Intellectual Property Office has granted a patent covering administration of laromestrocel, the Company’s proprietary mesenchymal stem cells, for the treatment of patients with symptoms of aging-related frailty and also for the treatment of non-ischemic dilated cardiomyopathy. Canadian Patent No. 3043594, entitled “Method of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity,” provides Longeveron with patent rights in Canada through 2037.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGVN:
- Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025
- Longeveron granted U.S. patent for administration of MSCs
- Longeveron Announces Resignation of Board Members
- Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments
- Longeveron Inc. Earnings Call: Mixed Sentiments Amid Clinical Progress